Twist Bioscience Corporation Common Stock (TWST) Stock Analysis
Market Closed
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy16 analystsWhat's happening with TWST
Price History
5-Year Weekly Candlestick Chart
Profile
Strong financial health; profitability, valuation, growth and earnings quality lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-0.8%)0/25
- P/S (29.8x)0/25
- EV/EBIT (n/a)10/25
- Growth25/100 · Weak
- Revenue CAGR (29.9%)25/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-38.7%)0/25
- ROE (-17.9%)0/25
- Net margin (-19.8%)0/25
- Operating margin (-33.9%)0/25
- Financial Health75/100 · Strong
- Altman Z (28.06)25/25
- Current ratio (2.70)25/25
- Interest coverage (-235.7x)0/25
- Net cash / debt (Net cash)25/25
- Quality35/100 · Weak
- Piotroski F (4/9)10/25
- Beneish M (-2.67)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 69.4%)0/25
About Twist Bioscience Corporation Common Stock
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. Show more
The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Headquarters: SOUTH SAN FRANCISCO, CA · Employees: 979 · Website ↗
Insider Transactions
Recent SEC Form 4 filings
- SellOpen market sale · filed 2026-09-23-348 sh2026-09-21
- SellOpen market sale · filed 2026-09-23-294 sh2026-09-21
- SellOpen market sale · filed 2026-09-23-1687 sh2026-09-21
- SellOption exercise · filed 2026-09-21-133269 sh2026-09-17
- SellOption exercise · filed 2026-09-21-75439 sh2026-09-17
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-0.8%D
Grade D: NegativeTTM FCF / Market Cap — vs own 5Y history: -32.6%–-0.8% · highest in history
P/S (TTM)29.79xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 2.9x–27.6x · highest in history
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales27.8xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio26.81xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-1.34A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-38.7%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-17.9%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-20.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-19.8%D
Grade D: LowNet Income / Revenue
Operating Margin-33.9%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin52.1%A
Grade A: PremiumGross Profit / Revenue
FCF Margin-23.2%D
Grade D: LowFCF / Revenue
True FCF Margin-38.9%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
75B+Altman Z-Score28.06A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.70xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio3.17xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-235.7xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Growth
25ERevenue CAGR29.9%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Implied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue15.7%D
Grade D: HighTTM stock-based comp / TTM Revenue
Quality
7/7 Loss Years35DPiotroski F-Score4/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.67A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability69.4%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue9.6%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.59xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$3.83
Cash & short-term investments per share (Finnhub)
Book Value / Share$7.80
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$171.67M
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$455.09M
Shareholders' equity (book value)
Asset / Liability3.06xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$12.20B
Current Market Capitalization
Beta2.25D
Grade D: High volatilityPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Company is effectively debt-free after netting cash.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 25, 2026
Key Insights: Twist Bioscience Corporation Common Stock (TWST)
Piotroski F-Score of 4/9 indicates mixed fundamentals for Twist Bioscience Corporation Common Stock. Altman Z-Score of 28.06 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.67 suggests a low likelihood of earnings manipulation. Revenue has compounded at roughly 30% annually — a strong growth profile. Free-cash-flow margin is negative (-23%) — the business currently burns cash.
- Company is effectively debt-free after netting cash.
- Interest coverage of -235.7× leaves little room for earnings shocks.
- Twist Bioscience Corporation Common Stock posted a net loss in 7 of 7 available completed fiscal years (2019–2025).
- At a valuation score of 20/100, TWST trades at a premium to its historical multiples.
See how TWST ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all TWST moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 24 | Regular | 182.89 | +15.39% | 3.44 |
| Sep 24 | After-hours | 184.05 | +16.12% | 3.59 |
Frequently Asked Questions about TWST
Is TWST stock a buy right now?
PreMarketPrice's quantitative model rates Twist Bioscience Corporation Common Stock's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is TWST stock overvalued?
Twist Bioscience Corporation Common Stock trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Twist Bioscience Corporation Common Stock report earnings?
No confirmed earnings date is currently scheduled for TWST. The Earnings section lists recent reports and updates as dates are announced.
What sector does Twist Bioscience Corporation Common Stock operate in?
Twist Bioscience Corporation Common Stock operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Twist Bioscience Corporation Common Stock do?
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
About Twist Bioscience Corporation Common Stock (TWST) Stock
Twist Bioscience Corporation Common Stock (TWST) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. Real-time pricing data for Twist Bioscience Corporation Common Stock is available on this page with a market capitalization of $12.2 billion. The financial health score for TWST is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for TWST stock.
TWST Stock Analysis & Key Metrics
On PreMarketPrice, you can track Twist Bioscience Corporation Common Stock (TWST) across multiple dimensions:
- Pre-market price & movement: Real-time TWST stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for TWST with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Twist Bioscience Corporation Common Stock across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for TWST.
- Sector peers: Compare TWST against 10 other healthcare stocks on key financial metrics.
Is TWST a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Twist Bioscience Corporation Common Stock (TWST) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Twist Bioscience Corporation Common Stock (TWST) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.